BiotechTube

CT-P63 + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV-2 Infection

Conditions

SARS-CoV-2 Infection

Trial Timeline

Oct 11, 2021 → Jan 25, 2022

NCT ID
NCT05017168

About CT-P63 + Placebo

CT-P63 + Placebo is a phase 1 stage product being developed by Celltrion for SARS-CoV-2 Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT05017168. Target conditions include SARS-CoV-2 Infection.

What happened to similar drugs?

4 of 20 similar drugs in SARS-CoV-2 Infection were approved

Approved (4) Terminated (1) Active (16)
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1083ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273.211ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
✅mRNA-1273 Variant-containing FormulationModernaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05017168Phase 1Completed

Competing Products

20 competing products in SARS-CoV-2 Infection

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1273ModernaPhase 1
0
mRNA-1283ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1273.214ModernaPhase 2
0
SPIKEVAXModernaPreclinical
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1083.1ModernaPhase 2
0
SPIKEVAX BivalentModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
mRNA-1273ModernaPhase 2
0
mRNA-1073ModernaPhase 2
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1273.211ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0